VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | DARA-KRd with MRD-based response-adapted therapy in newly diagnosed myeloma

Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, discusses the MASTER study (NCT03224507) which investigated the use of sequential daratumumab, carfilzomib, lenalidomide and dexamethasone (DARA-KRd) induction in newly diagnosed multiple myeloma with therapy duration guided by measurable residual disease (MRD). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter